The Tie-2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model
Ontology highlight
ABSTRACT: Background: The receptor tyrosine kinase TIE2 and its ligands, angiopoietins (ANGPTs), promote angiogenesis. In addition to expression on vascular endothelial cells, TIE2 is expressed on M2-like pro-tumorigenic macrophages. Thus, the TIE2 inhibitor rebastinib was developed as a potential therapy to address multiple cancers. The objective of this study was to determine the effects of rebastinib alone and combined with chemotherapy in a syngeneic murine model of ovarian cancer.
ORGANISM(S): Mus musculus
PROVIDER: GSE272411 | GEO | 2024/07/18
REPOSITORIES: GEO
ACCESS DATA